Pathogen-Specific Bloodstream Infections Associated With Tumour Necrosis Factor-α Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case-Control Study 2010-2024. (PubMed, Aliment Pharmacol Ther) - Sep 25, 2026 - "TNFi use was associated with increased BSI rates in patients with IBD, whereas vedolizumab and ustekinumab use was not. Overall, the findings suggest potential differences in infection risk across biologic therapies and in pathogen-specific susceptibility."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Oncology
|
|
Alessandra Meddis; Cæcilie Leding; Johan Burisch; Jon Gitz Holler; Thomas Benfield
|